Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib withdrawal trial in pediatric non-systemic juvenile idiopathic arthritis
MOH_2019-09-04_002413Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of baricitinib in juvenile idiopathic arthritis (JIA) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Primary efficacy objective. Started Jul 2019; status: completed.
02
Drugs
baricitinib
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on MOH_2019-09-04_002413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-09-04_002413.